Laurus Labs Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Laurus Labs Ltd. on BSE

Load latest

Laurus Labs Ltd.

11 Mar 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Laurus Labs Limited is pleased to announce that the Company has received a final approval from United States Food and Drug Administration (US FDA) for Hydroxychloroquine Tablets 200 mg. In another development, the Company also received a tentative approval for an ANDA for ADL (Abacavir, Dolutegravir, and Lamivudine) Tablets 600 mg/50 mg/300 mg from USFDA. The products will be commercialized from Laurus' manufacturing site located at Atchutapuram, Visakhapatnam. A press release to this extent is also attached for your information and records.

pdf

Laurus Labs Ltd.

21 Feb 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Laurus Labs Intimates about Schedule of Analyst/ Institutional Investor Meetings to be conducted on February 21, 2019 with Kotak Institutional Equities - Chasing Growth 2019 in One-on-One/Group Meetings at Mumbai. We request you to please take the same on record.

pdf

Laurus Labs Ltd.

08 Feb 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Laurus Labs Limited Q3 FY2019 Earnings Conference Call dated February 01, 2019 Outcome is attached herewith.

pdf

Laurus Labs Ltd.

03 Feb 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Laurus Labs Ltd is pleased to announce that the Company has received tentative approval from United States Food and Drug Administration (US FDA) under PEPFAR for Tenofovir/Lamivudine/Dolutegravir (TLD) 300/300/50mg fixed dose combination (FDC). Laurus Labs also received an Establishment Inspection Report (EIR) from USFDA for its Unit 6 on February 2, 2019. The manufacturing unit 6 was inspected by the regulatory agency in the month of November 2018 and is located at APSEZ, Atchutapuram, Visakhapatnam, Andhra Pradesh. A press release to this extent is also attached for your information and records.

pdf

Laurus Labs Ltd.

31 Jan 2019

605.95

1.80%

Investor Presentation

Laurus Labs Ltd - 540222 - Laurus Labs Investors/Analysts Presentation

BSE India

Please refer to our letter dated January 28, 2019, wherein we have intimated the schedule of Investors/Analysts call to be held on February 01, 2019. In this connection, we enclose herewith the presentation to the Investors/Analysts on the Unaudited Financial Results of the Company for the Quarter and Nine Months period ended December 31, 2018. The presentation is also being uploaded on the website of the Company - www.lauruslabs.com. Please take the information on record.

pdf

Laurus Labs Ltd.

31 Jan 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Laurus Labs Unaudited Financial Results For The Quarter And Nine …

BSE India

Please find herewith the Press Release of the Results of the Quarter and Nine Months period ended December 31, 2018.

pdf

Laurus Labs Ltd.

31 Jan 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Laurus Labs Unaudited Financial Results For The Quarter And Nine …

BSE India

Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Unaudited Financial Results of the Company for the Quarter and Nine Months period ended December 31, 2018 as approved by the Board of Directors of the Company in their Meeting held on January 31, 2019 along with the Limited Review Report issued by the Statutory Auditors of the Company. We have also uploaded the financial results on the website of the Company, namely www.lauruslabs.com and also on the websites of BSE Ltd. and National Stock Exchange of India Ltd. viz. www.bseindia.com and www.nseinda.com respectively. This is for your information and records.

pdf

Laurus Labs Ltd.

28 Jan 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Laurus Labs Ltd. will organize a conference call for Investors and Analysts, on Friday, February 01, 2019 at 4:00 pm IST. The conference call will be initiated with a brief management discussion on the Q3 & 9M FY2019 results which will be declared on January 31, 2019. This will be followed by an interactive Question & Answer session. The call will be hosted by Kotak Institutional Equities.

pdf

Laurus Labs Ltd.

28 Jan 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

pdf

Laurus Labs Ltd.

23 Jan 2019

605.95

1.80%

Corp. Note

Laurus Labs Ltd - 540222 - Board Meeting Intimation for Laurus Labs Board Meeting On January …

BSE India

Laurus Labs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2019 ,inter alia, to consider and approve Laurus Labs Limited Board of Directors'' Meeting will be held on Thursday, January 31, 2019, inter-alia, to consider and approve the Unaudited Financial Results of the Company for the quarter and nine months period ended December 31, 2018. Further, this is to inform you that the Company's trading window for dealing in securities by the Directors and Designated Persons shall be closed from Wednesday, January 23, 2019 to Saturday, February 2, 2019 (both days inclusive). This is for your information and records.

pdf

Is Laurus Labs Ltd. worth buying?

1218 Votes:

Buy 79.56%

Sell 10.84%

Hold 9.61%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Hold SEE REPORTS >

pdf